Table 5.
Ref. | Genotype | Duration | Interferon treatment | Ribavirin treatment | |
Apolinario et al[9] | Multi-centerpatients | 1 | 48 wk | 180 μg peg-INF-α-2a once weekly | 800 mg per day or 1000 mg < 75 kg, 1200 mg > 75 kg |
Non-1 | 24-48 wk | ||||
Out patiens | 1 | 48 wk | peg-INF-α2b 1.5 μg/kg per week | 1000-1200 mg per day | |
Non-1 | 24 wk | ||||
Lagging et al[34] | 1 | 6 wk1 | 180 μg peg-INF-α-2a once weekly | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Diago et al[7] | 1 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week or 180 μg peg-INF-α-2a/week | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Non-1 | 24 wk | ||||
Fattovich et al[21] | 1 and 4 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week or 180 μg peg-INF-α-2a/week | 800-1200 mg per day | |
2 and 3 | 24 wk | ||||
Kurelac et al[33] | 1 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week | Weight based ribavirin treatment2 | |
Darling et al[31] | 1 | 48 wk | 180 μg peg-INF-α-2a once weekly | 1000-1200 mg per day | |
Derbala et al[32] | 4 | 48 wk | Peg-IFN once weekly3 | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Al-Ashgar[19] | 4 | 48 wk | 180 μg peg-INF-α-2a once weekly | 1000 mg < 75 kg, 1200 mg > 75 kg |
After 6 wk, patients were randomized to differentiated treatment regimes;
No further information on ribavirin treatment was provided;
No further information on the subtype of peg-IFN was provided. Apolinario et al[9] feature patients from both an outpatient clinic as well as patients from two multicenter trials receiving different treatment regimens, illustrated by the segregation in the genotype column. peg-IFN: Pegylated interferon.